Start New EnglishEspañol中文РусскийالعربيةTiếng ViệtFrançaisDeutsch한국어Tagalog Library Performance
BETA v.3.0

2025 ICD-10-CM code D47.2

Monoclonal gammopathy of undetermined significance (MGUS). This condition is characterized by the presence of an abnormal protein (M protein) in the blood, produced by plasma cells in the bone marrow, without other symptoms or related conditions.

Code D47.2 should not be used if the patient has evidence of multiple myeloma, Waldenström macroglobulinemia, amyloid light-chain (AL) amyloidosis, or other related plasma cell disorders. Use the appropriate code for the diagnosed condition.

Medical necessity for the evaluation and management of MGUS lies in the potential for progression to malignancy, requiring ongoing monitoring.The frequency of monitoring is guided by risk stratification based on M protein type and quantity, as well as other clinical factors.

Diagnosis of MGUS typically involves laboratory tests such as complete blood count (CBC), comprehensive metabolic panel (CMP), serum protein electrophoresis (SPEP), immunofixation electrophoresis (IFE), and urine protein electrophoresis (UPEP).A bone marrow biopsy may be performed to assess plasma cell percentage and rule out other conditions.Monitoring for disease progression may involve periodic SPEP and IFE testing.

In simple words: MGUS is a condition where your body makes an abnormal protein, but it's not causing any harm yet. It's like a warning sign, and doctors keep an eye on it to make sure it doesn't develop into something more serious.

Monoclonal gammopathy of undetermined significance (MGUS) is defined by the presence of a monoclonal protein (M protein), typically identified through serum protein electrophoresis, in the blood. The M protein is produced by a single clone of plasma cells in the bone marrow. In MGUS, the level of the M protein is below a specific threshold (usually less than 3 g/dL), and there is no evidence of other related conditions like multiple myeloma or other lymphoproliferative disorders. Furthermore, individuals with MGUS do not experience the related organ or tissue damage that characterize multiple myeloma, such as anemia, bone lesions, kidney problems, or hypercalcemia.While MGUS can sometimes progress to a malignant condition, many individuals remain asymptomatic and do not develop further complications.

Example 1: A 65-year-old patient undergoing routine blood work is found to have an M protein on SPEP. Further tests reveal the level is below 3 g/dL, bone marrow biopsy shows less than 10% plasma cells, and there are no signs of organ damage. The patient is diagnosed with MGUS and scheduled for monitoring., A 70-year-old patient with a history of osteoporosis undergoes a skeletal survey, incidentally revealing a small, unexplained bone lesion.Subsequent SPEP reveals a low-level M protein, prompting further investigation for MGUS or related conditions. , A patient presents with fatigue and weakness. Blood tests reveal an elevated total protein level. Subsequent SPEP and IFE identify a monoclonal protein.Further evaluation including bone marrow biopsy and imaging studies are conducted to determine if the patient has MGUS, multiple myeloma, or another related condition.

Documentation for D47.2 should include results of SPEP, IFE, UPEP (if performed), bone marrow biopsy results (if performed), and the absence of symptoms and signs related to multiple myeloma or other related plasma cell disorders.It should be clearly stated that the monoclonal gammopathy is of undetermined significance.

** Only Enterprise users with EHR integration can access case-specific answers. Click here to request access.

Discover what matters.

iFrame™ AI's knowledge is aligned with and limited to the materials uploaded by users and should not be interpreted as medical, legal, or any other form of advice by iFrame™.